| diabetes type 2 | versus placebo or control No demonstrated result for efficacy chlorthalidone inferior to placebo in terms of Fatal and nonfatal MI in SHEP (diabetic subgroup), 1996 | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| SHEP (diabetic subgroup), 1996 | chlorthalidone vs placebo | Cardiovascular events 0.66 [0.46; 0.94] | Fatal and nonfatal MI 0.56 [0.32; 0.97] | All deaths 0.74 [0.46; 1.19] Stroke 0.74 [0.45; 1.19] |
| Trial | Treatments | Patients | Method |
|---|
| SHEP (diabetic subgroup), 1996 | low dose of chlorthalidone (12.5-25.0 mg/d) with a step-up to atenolol (25.0-50.0 mg/d) or reserpine (0.05-0.10 mg/d) if needed (n=283) vs. placebo (n=300) | men and women aged 60 years and older , non-insulin-treated diabetic (sub group) patients with isolated systolic hypertension (systolic BP >= 160 mm Hg; diastolic BP, <90 mm Hg) | double-blind Parallel groups Sample size: 283/300 Primary endpoint: not defined FU duration: 5 year |
|
| hypertension | versus placebo or control No demonstrated result for efficacy chlorthalidone inferior to placebo in terms of Coronary event in SHEP, 1991 chlorthalidone inferior to placebo in terms of Heart failure in SHEP, 1991 chlorthalidone inferior to placebo in terms of Stroke in SHEP, 1991 chlorthalidone inferior to placebo in terms of Fatal and nonfatal MI in SHEP (diabetic subgroup), 1996 | 6 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| VA-NHLBI, 1977 | chlorthalidone vs placebo | | | cardiovascular death ∞ [NaN; ∞] All-cause death ∞ [NaN; ∞] Coronary event 1.59 [0.52; 4.82] Cardiovascular death ∞ [NaN; ∞] Heart failure 1.59 [0.52; 4.82] Stroke NaN [NaN; NaN] cardiovascular event 1.59 [0.52; 4.82] | | SHEP, 1991 | chlorthalidone vs placebo | cardiovascular event 0.70 [0.61; 0.80] | Coronary event 0.74 [0.58; 0.95] Heart failure 0.52 [0.38; 0.71] Stroke 0.65 [0.51; 0.83] | cardiovascular death 0.81 [0.61; 1.06] All-cause death 0.88 [0.74; 1.05] Cardiovascular death 0.81 [0.61; 1.06] | | SHEP-pilot, 1989 | chlorthalidone vs placebo | | | cardiovascular death 0.68 [0.25; 1.85] cardiovascular event 0.65 [0.35; 1.22] | | SHEP (diabetic subgroup), 1996 | chlorthalidone vs placebo | Cardiovascular events 0.66 [0.46; 0.94] | Fatal and nonfatal MI 0.56 [0.32; 0.97] | All deaths 0.74 [0.46; 1.19] Stroke 0.74 [0.45; 1.19] | | SHEP-P (subgroup ), 1989 | chlorthalidone vs placebo | Stroke 0.21 [0.05; 0.96] | | All cause death ∞ [NaN; ∞] coronary death ∞ [NaN; ∞] coronary event ∞ [NaN; ∞] cardiovascular death ∞ [NaN; ∞] Heart failure ∞ [NaN; ∞] fatla stroke NaN [NaN; NaN] cardiovascular event 0.64 [0.20; 2.10] | | SHEP (subgroup ), 1991 | chlorthalidone vs placebo | Heart failure 0.35 [0.18; 0.67] Stroke 0.53 [0.32; 0.89] cardiovascular event 0.67 [0.47; 0.94] | | All cause death 0.93 [0.67; 1.30] coronary death 0.75 [0.38; 1.48] coronary event 0.70 [0.40; 1.25] cardiovascular death 0.83 [0.50; 1.39] fatla stroke 0.72 [0.16; 3.20] |
| Trial | Treatments | Patients | Method |
|---|
| VA-NHLBI, 1977 | chlorthalidone 50mg/d (n=508) vs. placebo (n=504) | patients aged 21 to 50 years with diastolic BP between 85 to 105 mm Hg | Double aveugle Sample size: 508/504 Primary endpoint: FU duration: 1.4 y | | SHEP, 1991 | chlorthalidone, 12.5 mg/d , chlorthalidone, 12.5 mg/d , chlorthalidone, 12.5 mg/d (n=2365) vs. placebo (n=2371)
| patients aged 60 years and above with Systolic BP between 160 and 219 mm Hg and diastolic BP less than 90 mm Hg
| Double blind Sample size: 2365/2371 Primary endpoint: FU duration: 4.4 y
| | SHEP-pilot, 1989 | chlorthalidone (n=443) vs. placebo (n=108) | elderly participants with untreated blood pressures of greater than 160/less than 90 mm Hg | double blind Sample size: 443/108 Primary endpoint: FU duration: 2.8y | | SHEP (diabetic subgroup), 1996 | low dose of chlorthalidone (12.5-25.0 mg/d) with a step-up to atenolol (25.0-50.0 mg/d) or reserpine (0.05-0.10 mg/d) if needed (n=283) vs. placebo (n=300) | men and women aged 60 years and older , non-insulin-treated diabetic (sub group) patients with isolated systolic hypertension (systolic BP >= 160 mm Hg; diastolic BP, <90 mm Hg) | double-blind Parallel groups Sample size: 283/300 Primary endpoint: not defined FU duration: 5 year | | SHEP-P (subgroup ), 1989 | chlorthalidone (n=70) vs. placebo (n=15) | elderly participants with untreated blood pressures of greater than 160/less than 90 mm Hg | double-blind Sample size: 70/15 Primary endpoint: FU duration: 2·8y | | SHEP (subgroup ), 1991 | chlorthalidone, 12.5 mg/d for step 1 (n=331) vs. placebo (n=319) | patients aged 60 years and above | double blind Sample size: 331/319 Primary endpoint: Nonfatal and fatal (total) stroke FU duration: 4·2y |
|
